5 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 4.1% per year over the past 4 years.
Net income has grown slower than revenue (-1.9% vs 4.1% per year).
Operating margin has contracted, at 13.4% in the latest year.
Free cash flow has grown 2.6% per year over the past 4 years.
Financial health
Total debt ($10.5B) exceeds cash ($4.5B); net debt is $6.0B.
Total debt has grown faster than revenue (8.3% vs 4.1% per year).
Operating income covered interest expense 6.3× in the latest year, down from 70× 4 years ago.
Total debt is 3.8× EBITDA.
Shareholder returns
Dividends have been paid for 3 consecutive years, consuming 3.1% of earnings and 4.3% of free cash flow.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
2025
$20.6B
$2.1B
40.0%
13.4%
$1.5B
$10.5B
$4.5B
2024
$19.7B
$2.0B
41.7%
13.3%
$1.6B
$10.5B
$2.9B
2023
$19.6B
$1.6B
40.5%
12.5%
$1.7B
$10.4B
$2.5B
2022
$18.3B
$1.9B
39.1%
13.8%
$1.8B
$8.3B
$1.4B
2021
$17.6B
$2.2B
40.8%
15.9%
$1.4B
—
—
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
Mar '26
$5.1B
$389M
38.5%
10.0%
$112M
$10.1B
$2.3B
Dec '25
$5.7B
$589M
39.7%
14.5%
—
$10.5B
$4.5B
Sep '25
$5.1B
$446M
38.7%
12.7%
—
$12.3B
$4.0B
Jun '25
$5.0B
$486M
39.6%
13.1%
$8M
$12.3B
$3.7B
Mar '25
$4.8B
$564M
42.1%
13.2%
$98M
$10.8B
$2.5B
Dec '24
$5.3B
$721M
42.8%
15.1%
—
$10.5B
$2.9B
Sep '24
$4.9B
$470M
41.7%
13.9%
—
$11.3B
$3.5B
Jun '24
$4.8B
$428M
41.4%
12.6%
-$183M
$10.2B
$2.0B
Mar '24
$4.7B
$374M
40.9%
11.6%
$274M
$10.3B
$2.6B
Dec '23
$5.2B
$403M
41.4%
13.2%
—
$10.4B
$2.5B
Sep '23
$4.8B
$375M
40.1%
12.8%
$570M
$10.3B
$2.4B
Jun '23
$4.8B
$418M
40.3%
11.8%
-$137M
$10.2B
$1.9B
Mar '23
$4.7B
$372M
40.2%
11.9%
$325M
$10.2B
$2.3B
Dec '22
$4.9B
$554M
39.1%
15.7%
—
$8.3B
$1.4B
Sep '22
$4.6B
$487M
38.7%
13.2%
—
—
—
Jun '22
$4.5B
$485M
40.1%
14.1%
—
—
—
Mar '22
$4.3B
$389M
38.6%
11.7%
—
—
—
Valuation over time
How the market has priced GEHC against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-earnings ratio has fallen from 19.5× (Mar '23) to 14.2× (Jun '26).
The price-to-sales ratio has fallen from 2.0× (Mar '23) to 1.4× (Jun '26).
The dividend yield has risen from 0.1% (Jan '24) to 0.2% (Jun '26).
Price / earnings (P/E)
P/E
Price / sales (P/S)
P/S
Dividend yield (%)
Dividend yield %
Frequently asked questions
Is GEHC growing its revenue and profit?
Over the past 4 years, GE HealthCare's revenue has grown 4.1% per year, and net income declined 1.9% per year. These are computed facts, not advice.
How much debt does GEHC have?
As of FY2025, GE HealthCare reported $10.5B of total debt against $4.5B of cash; operating income covered interest expense 6.3×.
What is GEHC's profit margin?
In FY2025, gross margin was 40.0%, operating margin 13.4%, and net margin 10.1%.
What is GEHC's P/E ratio?
As of Jun '26, GE HealthCare traded at a price-to-earnings ratio of about 14.2× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.